Amorfix developing ALS diagnostic tool

Amorfix Life Sciences (TSX:AMF) is developing a blood test to be used as a diagnostic tool for amyotrophic lateral sclerosis (ALS) based on initial ground breaking scientific study results of its CSO, Dr. Neil Cashman, and colleagues at UBC, who have shown that misfolded SOD1 is present in the blood of ALS patients. Amorfix said [...]

Cangene in research pact for Alzheimer’s

Cangene (TSX:CNJ) has signed a collaborative research agreement with the University of British Columbia to develop the work of Dr. Neil Cashman, scientific director of PrioNet Canada and Canada Research Chair in Neurodegeneration and Protein Misfolding at UBC, aimed at developing immune-based therapies for Alzheimer’s disease. Cangene became interested in the program following a recent [...]

Amorfix suspends blood testing for vCJD

Amorfix Life Sciences (TSX:AMF) has suspended development to commercialize its blood test for variant Creutzfeldt-Jakob disease (vCJD) after two new recently developed versions of the test did not yield positive results. “Although we were able to achieve unprecedented sensitivity with brain prions diluted into blood, we have been unable to detect blood prions with the [...]